CA3225305A1 - Compositions and methods for inhibiting creatine transport as a treatment for cancer - Google Patents

Compositions and methods for inhibiting creatine transport as a treatment for cancer Download PDF

Info

Publication number
CA3225305A1
CA3225305A1 CA3225305A CA3225305A CA3225305A1 CA 3225305 A1 CA3225305 A1 CA 3225305A1 CA 3225305 A CA3225305 A CA 3225305A CA 3225305 A CA3225305 A CA 3225305A CA 3225305 A1 CA3225305 A1 CA 3225305A1
Authority
CA
Canada
Prior art keywords
cancer
acid
creatine
kras
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3225305A
Other languages
English (en)
French (fr)
Inventor
Masoud TAVAZOIE
Isabel KURTH
David DARST
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspirna Inc
Original Assignee
Inspirna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspirna Inc filed Critical Inspirna Inc
Publication of CA3225305A1 publication Critical patent/CA3225305A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3225305A 2021-07-20 2022-07-19 Compositions and methods for inhibiting creatine transport as a treatment for cancer Pending CA3225305A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163223926P 2021-07-20 2021-07-20
US63/223,926 2021-07-20
PCT/US2022/073884 WO2023004308A1 (en) 2021-07-20 2022-07-19 Compositions and methods for inhibiting creatine transport as a treatment for cancer

Publications (1)

Publication Number Publication Date
CA3225305A1 true CA3225305A1 (en) 2023-01-26

Family

ID=84979767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3225305A Pending CA3225305A1 (en) 2021-07-20 2022-07-19 Compositions and methods for inhibiting creatine transport as a treatment for cancer

Country Status (6)

Country Link
US (1) US20240180912A1 (https=)
EP (1) EP4373582A4 (https=)
JP (1) JP2024528705A (https=)
AU (1) AU2022316200A1 (https=)
CA (1) CA3225305A1 (https=)
WO (1) WO2023004308A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
CN116602948B (zh) * 2023-06-06 2024-12-06 湖南岳靶生物医药有限公司 一种可用于降低膀胱癌细胞耐药性的化合物、组合物及其应用
WO2025114580A1 (en) * 2023-11-30 2025-06-05 National And Kapodistrian University Of Athens N-aminoguanidine derivatives with anticancer activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3736022A3 (en) * 2012-10-31 2021-01-20 The Rockefeller University Treatment and diagnosis of colon cancer
US20180002702A1 (en) * 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
WO2021062157A1 (en) * 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
UA128683C2 (uk) * 2019-10-22 2024-09-25 Люпін Лімітед Фармацевтична комбінація на основі інгібіторів prmt5
JP2023505687A (ja) * 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド 癌の処置方法

Also Published As

Publication number Publication date
AU2022316200A1 (en) 2024-01-25
EP4373582A1 (en) 2024-05-29
US20240180912A1 (en) 2024-06-06
WO2023004308A1 (en) 2023-01-26
EP4373582A4 (en) 2025-11-05
JP2024528705A (ja) 2024-07-30

Similar Documents

Publication Publication Date Title
US12502368B2 (en) Treatment and diagnosis of melanoma
US20240180912A1 (en) Compositions and methods for inhibiting creatine transport as a treatment for cancer
US20190125745A1 (en) Treatment and diagnosis of cancer
US20230338314A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
US20210290788A1 (en) Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
EP4524567A2 (en) G protein-coupled receptor (gpcr) modulation by imipridones
AU2024219839A1 (en) Imipridones for gliomas
US10717704B2 (en) Inhibitors of creatine transport and uses thereof
WO2017035331A1 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
TW202337501A (zh) 靶向ｐｓｍａ之放射性藥物及檢查點抑制劑之組合療法
TW202317204A (zh) 放射免疫結合物及檢查點抑制劑組合療法
WO2016176636A1 (en) Inhibitors of creatine transport and uses thereof
KR20250056926A (ko) 신경교종 치료를 위한 약학적 조성물 및 이의 용도
TW202337451A (zh) Ｎｔｓｒ１靶向放射性藥物及ｄｎａ損傷反應抑制劑之組合療法
IL323688A (en) PSMA-targeted radiopharmaceuticals and combination therapy with DNA damage response inhibitors
TW202337450A (zh) Ｎｔｓｒ１靶向放射性藥物及檢查點抑制劑之組合療法
JP2022545687A (ja) ポジオチニブとｖｅｇｆｒ２阻害剤との組み合わせおよびその使用方法
HK1235391B (en) Inhibitors of creatine transport and uses thereof
HK1257822B (en) Pharmaceutically acceptable salts of beta-guanidinopropionic acid with improved properties and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250210

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250711

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250711